FCN3 and adenoma: Earlier, Rasmussen et al.30 found no discriminating potency of ficolin-3 between cancer patients in general and healthy individuals or persons with non-malignant diseases while Storm et al.28 reported its rather weak potential to differentiate between colorectal cancer and adenoma patients (but not controls).